An open label multi facilities cooperation randomized control trial to verify postprandial hyperglycemia and hypertriglyceridemia improving effects of DIMS therapy in type 2 diabetes. reducing effect of olmesartan therapy in diabetic nephropathy.

An open label multi facilities cooperation randomized control trial to verify postprandial hyperglycemia and hypertriglyceridemia improving effects of DIMS therapy in type 2 diabetes. reducing effect of olmesartan therapy in diabetic nephropathy. - DIMS Improves glucose and lipids Metabolism in type 2 diabetes Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001645

Enrollment

Registered

2009-03-01

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type-2 diabetic patient who has been being hospitalized in our facilities is bedridden and takes liquid diet.

Interventions

This Study is a prospective randomized control trial. The entry period of this study is one year. Subjects are type-2 diabetes, who has taken liquid diets. The subjects are randomly assigned to two gr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Including criteria This study subject is assumed to meet the following requirements with type-2 diabetes hospitalized in our facilities. 1) Subject who has been hospitalized in our facilities is bedridden and takes liquid diet. 2) Neither the calorie of the liquid diet nor the content have been changed for three months or more. 3) It has already been diagnosed as the diabetic or fasting blood glucose level is 126mg/dl or more. 4) It is necessary that the age is 20 years old or more. Sex is not asked.

Exclusion criteria

Exclusion criteria: Excluding criteria 1) Patient who suffers from serious diseases. 2) Patient who suffers from malignant diseases. 3) Subjects of having received dialysis. 4) Patient who has already taken low carbohydrate liquid diet. 5) Patient that there is allergy in element of liquid diet.

Design outcomes

Secondary

Measure	Time frame
Secondary endpoints: Changes of urinary C-peptide excretion (CPR), fatty acids (FA), HDL-cholesterol (HDL-C), total cholesterol (TC), remnant like particle (RLP)-TG, apolipoprotein B, apolipoprotein AI, adiponectine, tumor necrosis factor (TNF) alpha, plasma monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, urinary 8-epi prostaglandin F2alpha (8-epi) 8-hydroxydeoxyguanosine(8-OHdG), albumin excretion (albumin to creatinine ratio: ACR), blood pressure (BP) and body weight (BW).	—

Measure

Time frame

Secondary endpoints: Changes of urinary C-peptide excretion (CPR), fatty acids (FA), HDL-cholesterol (HDL-C), total cholesterol (TC), remnant like particle (RLP)-TG, apolipoprotein B, apolipoprotein AI, adiponectine, tumor necrosis factor (TNF) alpha, plasma monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, urinary 8-epi prostaglandin F2alpha (8-epi) 8-hydroxydeoxyguanosine(8-OHdG), albumin excretion (albumin to creatinine ratio: ACR), blood pressure (BP) and body weight (BW).

—

Primary

Measure	Time frame
Primary endpoints: Changes of fasting and postprandial 2-hr plasma glucose levels, HbA1c, fasting and postprandial 2- and 4-hr serum triglyceride levels.	—

Countries

Japan

Contacts

Public ContactSusumu Ogawa MD,PhD

Tohoku University Hospital Division of Nephrology, Endocrinology and Hypertension

ogawa-s@m.tains.tohoku.ac.jp022-717-7266

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026